Skip to content
Company Analysis

Pulse Biosciences, Inc PLSE

A comprehensive view of key metrics, scores, and financial health for Pulse Biosciences, Inc

Overview of Pulse Biosciences, Inc.

PLSE NCM
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics Small Cap
Pulse Biosciences, Inc. (PLSE), is a Small Cap company, in the Medical Instruments & Supplies industry, last closed at $24.37, about 0.0% overvalued vs fair value, +54.5% 1Y return, ranked 1057/1122 in sector.
Metrics ROE -74.5% Gross Margin -360.0%
USD 24.37
-9.37%
(Delayed)
• Vol 90d: 116.1%
52-Week Range
Market Cap
$1.86B
Enterprise Value
$1.79B
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 78%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.pulsebiosciences.c...
HQ Miami, FL
Employees 116
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$-2
$-2
$-2
Current: $24.37

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$350.0K
Gross Profit
$-1.3M
-7%%
Operating Income (GAAP)
$-76.9M
-36.8%%
EBITDA
$-71.7M
-30.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
-360.0%
Poor

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Pulse Biosciences, Inc's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
12
/100
Weak
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
1
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing PLSE's balance between Growth (17.4%), Profitability (15.2%), and Safety (67.3%). Growth 17% Safety 67% Profitability 15%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

11th percentile vs peers
11
Key Signals
EPS Growth YoY -8.1% 28p Revenue CAGR 3Y -20.6% 7p Asset Growth YoY -27.4% 13p Rev Growth YoY -1.00 1p
Strengths
  • Equity/Assets in top 20% of peers (83.9%, 85th percentile)
Risks
  • Growth in bottom 20% of peers (percentile: 11)
  • Rev Growth YoY in bottom 20% of peers (-1.00)

Profitability

9th percentile vs peers
10
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

42th percentile vs peers
43
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Pulse Biosciences, Inc.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-1.56
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000